Elizabeth Gemba
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 27.2% of the total.
Across 133 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$581
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$485
- Johnson & Johnson$288
- Ironwood Pharmaceuticals, Inc$175
- Takeda Pharmaceuticals U.S.A., Inc.$144
- Pfizer$128
- plus $339 from 10 others
What the payments were for
- Food & beverage$2,139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $581 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 45 | $485 |
| Johnson & Johnson | 14 | $288 |
| Ironwood Pharmaceuticals, Inc | 10 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $144 |
| Pfizer | 6 | $128 |
| Sanofi | 3 | $67 |
| Ardelyx, Inc. | 3 | $66 |
| Aimmune Therapeutics, Inc. | 2 | $50 |
| Novo Nordisk | 2 | $45 |
| Lilly USA, LLC | 1 | $27 |
| Gilead | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Sandoz | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $4 |
How this compares
$2,139 in reported general payments places this provider in the 85th percentile of 124 medical providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 17 | $27,620 |
| LinzessLinaclotide | 18 | $13,641 |
| TrulancePlecanatide | 16 | $8,703 |
| Mesalamine | 18 | $6,682 |
| Esomeprazole Magnesium | 30 | $2,611 |
| Pantoprazole Sodium | 118 | $1,944 |
| Omeprazole | 114 | $1,277 |
| Dicyclomine Hcl | 55 | $1,028 |
| Famotidine | 82 | $871 |
| Nadolol | 13 | $528 |
| Lactulose | 13 | $436 |
| Ondansetron OdtOndansetron | 17 | $143 |
| Metoclopramide Hcl | 16 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $485 | $36,32333 claims |
| AbbVieLinzess | $581 | $13,64118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 medical providers in New Hampshire.
Other medical in Salem
- Holly PelletierManchester$124K
- Kathrine CecilNashua$9K
- Alyssa DunnDerry$8K
- Kelly HochstetlerDover$8K
- Stacy FilionConcord$5K
- Jacqueline FournierConcord$5K
- Andrea BourkeLondonderry$5K
- Heather BigosDover$5K
- Dagan CloutierNashua$4K
- Rachel WhitmanPortsmouth$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.